Tacrolimus Envarsus Xr denied for failing step therapy by Cigna?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Tacrolimus Envarsus Xr
## Why Cigna Denied Tacrolimus Envarsus XR Under Step Therapy
A step-therapy denial means Cigna requires you to try and fail — or document prior adequate trial of — a lower-cost tacrolimus formulation (typically immediate-release tacrolimus capsules) before approving the extended-release version. Step therapy for tacrolimus formulations is common: insurers treat the active molecule as the covered therapy and require clinical justification to move to a higher-cost formulation.
This type of denial is very commonly overturned when the record documents either (a) a prior adequate trial of immediate-release tacrolimus with documented clinical issues, or (b) a clinical reason why step therapy with the immediate-release formulation poses an unacceptable risk — for example, in a recently transplanted or immunologically unstable patient.
## Step-Therapy Protections
Many states have enacted step-therapy reform laws requiring insurers to honor documented step-therapy exceptions. For employer-sponsored plans governed by ERISA, federal law applies, but most plans still have a step-therapy exception process. Check whether your state has a step-therapy override law — your state insurance commissioner's website will list applicable protections.
## Your Federal Appeal Rights
- Step-therapy exception request: File this first, simultaneously with the prior authorization if applicable. The exception request is separate from but related to the appeal process.
- Internal appeal (ACA §2719): If the exception is denied, file a formal internal appeal within the window on your denial notice.
- External review: Following a final internal denial, non-grandfathered plans must offer independent external review, generally within approximately four months.
- ERISA §503: Employer-plan members are entitled to full-and-fair review, including the specific criteria applied for the step-therapy exception.
- Expedited review: If your transplant stability requires immediate access, request expedited review at every level simultaneously.
## What to Gather
1. Prior treatment history with outcomes: A dated log of every tacrolimus formulation you have used, with trough levels, tolerability notes, and any clinical events (rejection episodes, toxicity, variability). 2. Documentation of step completion or exemption: If you have already tried immediate-release tacrolimus, document it specifically. If you have not — and a trial would be clinically inappropriate — your prescriber must explain why. 3. Clinical stability records: Current lab trends, recent clinic notes, any biopsy data, and your transplant team's assessment of your immunologic risk level. 4. Prescriber step-therapy exception letter: Your transplant physician should state whether the step has been completed or is contraindicated for this patient, referencing the FDA-approved prescribing information for Envarsus XR and the applicable transplant guideline organization.
## Criteria-Mapping Structure
Obtain Cigna's step-therapy exception criteria from their coverage policy. For each criterion, record the chart fact that satisfies it:
| Step-Therapy Exception Criterion | Chart Documentation | |---|---| | [Prior trial requirement] | [Dates, formulation, outcome from records] | | [Clinical exception basis] | [Prescriber attestation / clinic note] |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →